Clinical Trials of interest to cytokine & interferon researchers huCART19-IL18 in NHL/CLL Patients ClinicalTrials.gov ID NCT04684563 Sponsor University of Pennsylvania Information provided by University of Pennsylvania (Responsible Party) Last Update Posted 2024-05-13 Low Dose IL-2 for the Treatment of Crohn’s Disease ClinicalTrials.gov ID NCT04263831 Sponsor Boston Children’s Hospital Information provided [READ MORE]
My main research interest now is the convergence between immunology and regenerative biology, and thus, the Franklin Lab is focused on understanding the way immune cells contribute to tissue remodeling and repair. The ICIS community has been so warm and welcoming! Being a member of ICIS has given me a [READ MORE]
“Vote early, vote often” is a humorous quip often attributed to the organized crime era of Chicago in the early 1900s. At the Cytokine Society we do not sanction multiple voting – but all members in good standing are encouraged to cast your ballot legitimately in the upcoming elections for [READ MORE]
Don’t miss this chance to learn from global thought leaders in Cytokine and Interferon research and gain the insights, techniques, and experiences you need to build a vital network and amplify your impact. Check out this preview of the invited speakers for Tuesday and Wednesday. View the full program here [READ MORE]
I’m very grateful to be part of the ICIS community, and in particular winning the Regeneron-ICIS New Investigator award last year was a huge boost for me just as I was starting my new lab. I am broadly interested in ligand-receptor systems that regulate tissue inflammation and repair (especially cytokines!). [READ MORE]
Voting for ICIS Leadership and a change to the Bylaws is open from July 1 – 31, 2024. All ICIS Members in good standing are eligible and encouraged to vote and exercise your right to determine the future of the International Cytokine and Interferon Society. Council and Nominations Committee Election [READ MORE]
On June 18, ICIS hosted the first-ever IL-9-focused symposium at the Federation of Clinical Immunology Societies (FOCIS) annual meeting. Devotees of all things IL-9 gathered in San Francisco to hear about “IL-9: from birth to breath.” The symposium was organized by IL-9 guru Mark Kaplan and newcomer (and Signals+ Co-Editor [READ MORE]
Clinical Trials of interest to cytokine & interferon researchers Non-Eosinophilic Biological Effects of IL-5 ClinicalTrials.gov ID NCT06026202 Sponsor Imperial College London Information provided by Imperial College London (Responsible Party) Last Update Posted 2023-10-30 A Study of 19-28z/IL-18 in People With Acute Lymphoblastic Leukemia (ALL) ClinicalTrials.gov ID NCT06287528 Sponsor Memorial Sloan [READ MORE]
With the 2024 ICIS Young Investigator Awards recently announced, Signals+ Editorial Board Member, Maialen Sebastian-delaCruz, took the opportunity to catch up with some of the YI Award Winners of past years and asked them to share their experiences and describe the impact this award had in their careers. For some [READ MORE]
Assessment of FOXP3 Gene Polymorphisms and Serum Interleukin 10 in Patients With ITP (FoxP3ITP) ClinicalTrials.gov ID NCT05410249 Sponsor Sohag University Information provided by Noha Saber Shafik, Sohag University (Responsible Party) Last Update Posted 2023-04-12 Targeting IL-17A for Treatment-Resistant Depression ClinicalTrials.gov ID NCT04979910 Sponsor Icahn School of Medicine at Mount Sinai [READ MORE]
International Cytokine & Interferon Society, Copyright 2024 Website Design by Rhema Association Management | Privacy Policy
